These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33328334)

  • 1. Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of Autoimmunity.
    Vlach J; Bender AT; Przetak M; Pereira A; Deshpande A; Johnson TL; Reissig S; Tzvetkov E; Musil D; Morse NT; Haselmayer P; Zimmerli SC; Okitsu SL; Walsky RL; Sherer B
    J Pharmacol Exp Ther; 2021 Mar; 376(3):397-409. PubMed ID: 33328334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay.
    Knoepfel T; Nimsgern P; Jacquier S; Bourrel M; Vangrevelinghe E; Glatthar R; Behnke D; Alper PB; Michellys PY; Deane J; Junt T; Zipfel G; Limonta S; Hawtin S; Andre C; Boulay T; Loetscher P; Faller M; Blank J; Feifel R; Betschart C
    J Med Chem; 2020 Aug; 63(15):8276-8295. PubMed ID: 32786235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Novel Small Molecule Dual Inhibitors Targeting Toll-Like Receptors
    Padilla-Salinas R; Anderson R; Sakaniwa K; Zhang S; Nordeen P; Lu C; Shimizu T; Yin H
    J Med Chem; 2019 Nov; 62(22):10221-10244. PubMed ID: 31687820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The functional effects of physical interactions among Toll-like receptors 7, 8, and 9.
    Wang J; Shao Y; Bennett TA; Shankar RA; Wightman PD; Reddy LG
    J Biol Chem; 2006 Dec; 281(49):37427-34. PubMed ID: 17040905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Evidence for the Glucocorticoid-Sparing Potential of a Dual Toll-Like Receptor 7/8 Inhibitor in Autoimmune Diseases.
    Deshmukh A; Pereira A; Geraci N; Tzvetkov E; Przetak M; Catalina MD; Morand EF; Bender AT; Vaidyanathan B
    J Pharmacol Exp Ther; 2024 Feb; 388(3):751-764. PubMed ID: 37673681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathway.
    Alper PB; Deane J; Betschart C; Buffet D; Collignon Zipfel G; Gordon P; Hampton J; Hawtin S; Ibanez M; Jiang T; Junt T; Knoepfel T; Liu B; Maginnis J; McKeever U; Michellys PY; Mutnick D; Nayak B; Niwa S; Richmond W; Rush JS; Syka P; Zhang Y; Zhu X
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127366. PubMed ID: 32738975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9.
    Kandimalla ER; Bhagat L; Wang D; Yu D; Sullivan T; La Monica N; Agrawal S
    Nucleic Acids Res; 2013 Apr; 41(6):3947-61. PubMed ID: 23396449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel Toll-like receptor 7/8-specific antagonist E6742 ameliorates clinically relevant disease parameters in murine models of lupus.
    Ishizaka ST; Hawkins L; Chen Q; Tago F; Yagi T; Sakaniwa K; Zhang Z; Shimizu T; Shirato M
    Eur J Pharmacol; 2023 Oct; 957():175962. PubMed ID: 37544422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides.
    Jurk M; Kritzler A; Schulte B; Tluk S; Schetter C; Krieg AM; Vollmer J
    Eur J Immunol; 2006 Jul; 36(7):1815-26. PubMed ID: 16783850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural analysis reveals TLR7 dynamics underlying antagonism.
    Tojo S; Zhang Z; Matsui H; Tahara M; Ikeguchi M; Kochi M; Kamada M; Shigematsu H; Tsutsumi A; Adachi N; Shibata T; Yamamoto M; Kikkawa M; Senda T; Isobe Y; Ohto U; Shimizu T
    Nat Commun; 2020 Oct; 11(1):5204. PubMed ID: 33060576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Analyses of Toll-like Receptor 7 Reveal Detailed RNA Sequence Specificity and Recognition Mechanism of Agonistic Ligands.
    Zhang Z; Ohto U; Shibata T; Taoka M; Yamauchi Y; Sato R; Shukla NM; David SA; Isobe T; Miyake K; Shimizu T
    Cell Rep; 2018 Dec; 25(12):3371-3381.e5. PubMed ID: 30566863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR7 and TLR8 Differentially Activate the IRF and NF-κB Pathways in Specific Cell Types to Promote Inflammation.
    Bender AT; Tzvetkov E; Pereira A; Wu Y; Kasar S; Przetak MM; Vlach J; Niewold TB; Jensen MA; Okitsu SL
    Immunohorizons; 2020 Feb; 4(2):93-107. PubMed ID: 32086319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-like receptor 8 deletion accelerates autoimmunity in a mouse model of lupus through a Toll-like receptor 7-dependent mechanism.
    Tran NL; Manzin-Lorenzi C; Santiago-Raber ML
    Immunology; 2015 May; 145(1):60-70. PubMed ID: 25424423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus.
    Embrechts W; Herschke F; Pauwels F; Stoops B; Last S; Pieters S; Pande V; Pille G; Amssoms K; Smyej I; Dhuyvetter D; Scholliers A; Mostmans W; Van Dijck K; Van Schoubroeck B; Thone T; De Pooter D; Fanning G; Jonckers THM; Horton H; Raboisson P; McGowan D
    J Med Chem; 2018 Jul; 61(14):6236-6246. PubMed ID: 29965759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of TLR7/8 small RNA antagonists.
    Sioud M
    Methods Mol Biol; 2010; 629():387-94. PubMed ID: 20387163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly-thymidine oligonucleotides mediate activation of murine glial cells primarily through TLR7, not TLR8.
    Du M; Butchi NB; Woods T; Peterson KE
    PLoS One; 2011; 6(7):e22454. PubMed ID: 21811614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of miRNA associated with a disease-specific signature and secreted via extracellular vesicles of systemic lupus erythematosus patients suppresses target organ inflammation in a humanized mouse model.
    Young NA; Schwarz E; Zeno BM; Bruckner S; Mesa RA; Jablonski K; Wu LC; Roberson EDO; Jarjour WN
    Front Immunol; 2023; 14():1090177. PubMed ID: 38939646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lupus Autoimmunity and Metabolic Parameters Are Exacerbated Upon High Fat Diet-Induced Obesity Due to TLR7 Signaling.
    Hanna Kazazian N; Wang Y; Roussel-Queval A; Marcadet L; Chasson L; Laprie C; Desnues B; Charaix J; Irla M; Alexopoulou L
    Front Immunol; 2019; 10():2015. PubMed ID: 31552019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TLR8 escapes X chromosome inactivation in human monocytes and CD4
    Youness A; Cenac C; Faz-López B; Grunenwald S; Barrat FJ; Chaumeil J; Mejía JE; Guéry JC
    Biol Sex Differ; 2023 Sep; 14(1):60. PubMed ID: 37723501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.
    Lan T; Kandimalla ER; Yu D; Bhagat L; Li Y; Wang D; Zhu F; Tang JX; Putta MR; Cong Y; Trombino AF; Sullivan T; Agrawal S
    Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13750-5. PubMed ID: 17698957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.